Publications by authors named "J Vadakara"
Background: Although VEGFR tyrosine kinase inhibitors (TKIs) are a preferred systemic treatment approach for patients with advanced renal cell carcinoma (RCC) and thyroid carcinoma (TC), treatment-related cardiovascular (CV) toxicity is an important contributor to morbidity. However, the clinical risk assessment and impact of CV toxicities, including early significant hypertension, among real-world advanced cancer populations receiving VEGFR TKI therapies remain understudied.
Methods: In a multicenter, retrospective cohort study across 3 large and diverse US health systems, we characterized baseline hypertension and CV comorbidity in patients with RCC and those with TC who are newly initiating VEGFR TKI therapy.
Angioedema occurs in less than 1-2% of the population and amongst these cases, those with acquired angioedema are less prevalent than hereditary angioedema. Amongst cases of acquired angioedema, studies have shown that they were highly linked with an associated lymphoproliferative disorder, suspected secondary to the production of neutralizing autoantibodies from pathological B cell proliferation. We present a case of a patient who presented with recurrent episodes of angioedema and was found to have low C4 and C1 esterase function, initially concerning for a hereditary angioedema variant, who was subsequently found to have marginal B cell lymphoma mimicking hereditary angioedema.
View Article and Find Full Text PDFArticle Synopsis
- The hematopoietic cellular therapy (HCT) pharmacist plays a vital role in the care team for patients undergoing transplantation, but integrating pharmacists into clinical settings is still a challenge.* -
- A study evaluated the implementation of a full-time HCT pharmacist at a rural Pennsylvania center over two years, documenting 1,531 patient encounters and addressing 2,156 medication-related issues with substantial positive outcomes in patient care.* -
- Patient satisfaction was high, with 76% of surveyed patients and caregivers reporting strong satisfaction, while pharmacy services expanded to support additional patient populations beyond just allogeneic transplants.*
Article Synopsis
- Immuno-oncotherapy (IO) has improved systemic cancer treatment outcomes but is associated with neurological complications, particularly from immune checkpoint inhibitors (ICIs).
- Common complications include autoimmune inflammatory responses affecting multiple organs, with neuroradiologic changes often misinterpreted as cancer progression.
- This review presents a case series highlighting neurological side effects linked to ICI therapy, emphasizing that accurate identification of these side effects can enhance patient care and treatment effectiveness.
Article Synopsis
- Current treatments for glioblastoma (GBM) often intervene too late, as most clinical trials focus on recurrent disease; the study proposes using a new imaging biomarker to detect progression earlier for better therapeutic opportunities.
- A review of over 600 GBM patients revealed that T2 FLAIR signal intensity (SI) changes can indicate disease progression up to 3.4 months before standard assessments, showing high sensitivity and correlating with worse patient outcomes.
- The findings suggest a need to rethink how GBM treatment response is assessed and to consider earlier intervention points in clinical trial designs to improve patient survival rates.